ArticleGastro hep advances2025
Validation of the American Association for the Study of Liver Disease/European Association for the Study of the Liver Multistep Screening Strategies for Metabolic Dysfunction-associated Steatotic Liver disease.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2025Article
- Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Multistep algorithms for noninvasive identification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD), such as the recent American Association for the Study of Liver Disease and European Association for the Study of the Liver MASLD guidelines aim to identify patients who require hepatology referral. We evaluated the performance of these algorithms in the National Health and Nutrition Examination Survey cohort. Methods: We analyzed 7768 adult participants from the National Health and Nutrition Examination Survey 2017-2020 with valid liver stiffness measurement (LSM) data. MASLD was defined as hepatic steatosis (controlled attenuation parameter measurement of ≥ 248 dB/m) with ≥1 cardiometabolic risk factor; significant fibrosis and advanced fibrosis were defined as LSM ≥8 kPa and ≥12 kPa respectively (with sensitivity analysis of 0-30kPa and using the FibroScan-aspartate aminotransferase or Agile algorithms). Results: A total of 44.8% (n = 3479) met metabolic risk criteria, 7.5% (n = 586) met raised Fibrosis-4 Index criteria, and 3.0% (n = 235) met referral criteria. The multistep pathway demonstrated high specificity but limited sensitivity for identifying MASLD with significant fibrosis (sensitivity 21%, 95% confidence interval [CI] 17%-25%) or advanced fibrosis (29%, 95% CI 23%-37%). Sensitivity was particularly low in key subgroups: age < 50 years (6%, 95% CI 3%-11%), women (15%, 95% CI 11%-21%) and patients without type 2 diabetes (16%, 95% CI 12%-20%). Sensitivity improved when targeting more advanced disease: 29% for advanced fibrosis (LSM ≥12 kPa), 54% for FibroScan-aspartate aminotransferase ≥0.67, 35% for Agile 3+ ≥0.68, and 66% for Agile 4 ≥ 0.57. Conclusion: A multistep screening strategy based on metabolic risk criteria, Fibrosis-4 Index, and LSM demonstrates high specificity but low sensitivity for detecting MASLD with significant fibrosis in a US-based populational cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.